Health

Vol.11 No.8(2019), Paper ID 94306, 11 pages

DOI:10.4236/health.2019.118080

 

Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy with Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study

 

Kyoko Nakazawa, Shota Saito, Masayuki Nagahashi, Akimitsu Yamada, Akira Toyama, Kouhei Akazawa

 

Department of Medical Informatics and Statistics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Department of Health Informatics, Niigata University of Health and Welfare, Niigata, Japan
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Kanagawa, Japan
Department of Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan
Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan

 

Copyright © 2019 Kyoko Nakazawa, Shota Saito, Masayuki Nagahashi, Akimitsu Yamada, Akira Toyama, Kouhei Akazawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Nakazawa, K. , Saito, S. , Nagahashi, M. , Yamada, A. , Toyama, A. and Akazawa, K. (2019) Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy with Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study. Health, 11, 1017-1027. doi: 10.4236/health.2019.118080.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.